Cite
HARVARD Citation
DiPippo, V. et al. (2016). Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. Prostate. 76 (3), pp. 325-334. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
DiPippo, V. et al. (2016). Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. Prostate. 76 (3), pp. 325-334. [Online].